Search results
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 2 days agoOn Monday, Deutsche Bank (ETR:DBKGn) reiterated a Hold rating and a price target of GBP110.00 on...
BMO maintains target on AstraZeneca shares, cites trial success By Investing.com
Investing.com· 2 days agoOn Wednesday, BMO Capital upheld its Outperform rating on AstraZeneca (NASDAQ:AZN) with a steady...
Data Science Hiring Process at AstraZeneca
Analytics India Magazine· 2 days agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 3 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 1 day agoThe American Society of Clinical Oncology held its annual conference in Chicago this past week,...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 2 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 2 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 4 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 4 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...